Galderma Group AG experienced a significant drop in its Zurich-listed stock, falling 6.6%, following a US Food and Drug Administration (FDA) Complete Response Letter for its new botulinum toxin product, relabotulinumtoxinA (marketed as Relfydess). This decision, announced on Wednesday, delays Galderma's anticipated entry into the commercially important US aesthetics market with a product designed to compete with AbbVie’s Botox. The FDA's concerns centered on observations made during a pre-license inspection of the manufacturing site and a request for analytical method optimization. Neither the safety nor efficacy portions of Galderma's application were found to have deficiencies, which is a positive for the long-term clinical argument for the product.
This is not Galderma's first encounter with FDA regulatory hurdles; the company previously faced a refusal in 2023 related to chemistry, manufacturing, and controls deficiencies. Analysts, including James Gordon of Barclays, noted that the current issues appear narrower. Jefferies' Benjamin Jackson estimated the delay for the next-generation neuromodulator could be around 9 to 12 months. This extended timeline is critical in the fast-growing neuromodulator market, where AbbVie's Botox currently dominates US sales, and it could pressure Galderma's broader pipeline and erode future market share.
Despite the US setback, Relfydess is already approved in 33 international markets and has launched in over 20, including Europe, the Middle East, Asia, and Australia, with positive feedback from healthcare professionals. Galderma, which already has a substantial neuromodulator business through Dysport, reported $364 million in neuromodulator sales in Q1 2026, representing a 12.5% year-on-year constant-currency growth. The broader injectable aesthetics category generated $648 million during the same period. Relfydess's unique selling proposition as a ready-to-use liquid formulation, unlike most rival products requiring reconstitution, aims to offer convenience and potentially rapid onset with durability approaching six months for some patients. This could allow Galderma to segment the market and strengthen cross-selling opportunities with its other products like Restylane and Sculptra. The company remains committed to resolving the FDA's observations and maintains an open dialogue with the agency.
